Calendario de promoción Cardiol Therapeutics Inc.
Horario avanzado
gráfico sencillo
Acerca de la empresa Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. más detallesIPO date | 2019-01-15 |
---|---|
ISIN | CA14161Y2006 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | cad |
Сайт | https://www.cardiolrx.com |
Цена ао | 1.95 |
Cambio de precio por día: | -0.7576% (1.32) |
---|---|
Cambio de precio por semana.: | +2.34% (1.28) |
Cambio de precio por mes: | -17.09% (1.58) |
Cambio de precio en 3 meses.: | -36.71% (2.07) |
Cambio de precio en seis meses: | -31.77% (1.92) |
Cambio de precio por año: | +55.4% (0.843) |
Cambio de precio en 3 años.: | -32.82% (1.95) |
Cambio de precio en 5 años.: | -55.58% (2.949) |
Cambio de precio en 10 años.: | 0% (1.31) |
Cambio de precio desde principios de año.: | -14.38% (1.53) |
|
Subestimación
|
Eficiencia
|
|||||||||||||||||||||||||||||||||||||
Dividendos
|
Deber
|
Impulso de crecimiento
|
Instituciones | Volumen | Compartir, % |
---|---|---|
MMCAP International, Inc. SPC | 2953300 | 4.33 |
AdvisorShares Investments, LLC | 1189978 | 1.75 |
Tejara Capital Ltd | 1116676 | 1.64 |
AXS Investments, LLC | 697651 | 1.02 |
Lion Street Advisors, LLC | 192700 | 0.28 |
Bank of Montreal/Can/ | 104479 | 0.15 |
We Are One Seven, LLC | 100000 | 0.15 |
Laird Norton Trust Company, LLC | 100000 | 0.15 |
Cambridge Investment Research Advisors Inc. | 85201 | 0.12 |
Credit Suisse Ag/ | 80000 | 0.12 |
ETF | Compartir, % | Rentabilidad del año, % | Dividendos, % |
---|---|---|---|
AdvisorShares Pure Cannabis ETF | 6.51027 | -3.73 | 1.68573 |
Supervisor | Título profesional | Pago | año de nacimiento |
---|---|---|---|
Mr. David G. Elsley MBA | President, CEO & Director | 550.14k | |
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA | CFO, Corporate Secretary & Director | 216.79k | |
Mr. Bernard Lim B.Sc. | Chief Operating Officer | 379.39k | |
Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer & Head of Research & Development | 549.01k | 1962 (63 año) |
Trevor Burns | Investor Relations | N/A | |
Mr. John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
DIRECCIÓN: Canada, Oakville, 2265 Upper Middle Road East - abrir en mapas de google, abrir mapas de Yandex
Sitio web: https://www.cardiolrx.com
Sitio web: https://www.cardiolrx.com